Welcome to our dedicated page for SYN news (Ticker: SYN), a resource for investors and traders seeking the latest updates and insights on SYN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SYN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SYN's position in the market.
Synthetic Biologics (NYSE American: SYN) announced that its oral drug SYN-020 was well tolerated in a Phase 1 clinical trial, with 32 healthy volunteers participating in doses from 5 mg to 75 mg over 14 days. The drug maintained a favorable safety profile with mild adverse events, primarily constipation. SYN-020 targets gastrointestinal inflammation and aims to address unmet medical needs in diseases like celiac disease and NAFLD. The company has also managed to overcome production cost hurdles, paving the way for potential clinical and commercial development.
Synthetic Biologics, Inc. (NYSE American: SYN) announced a conference call set for May 16, 2022, at 8:30 a.m. ET to review its financial results for Q1 2022 and offer a corporate update. Participants can join by dialing specific numbers or access the call via the company’s website. The company is in the clinical-stage, focusing on therapeutics for unmet medical needs. Recent activities include the acquisition of VCN Biosciences, which is advancing an innovative oncolytic adenovirus platform for cancer treatment.
Synthetic Biologics strengthens its oncology strategy by establishing a new Scientific Advisory Board (SAB) featuring leading experts in oncolytic viruses and gene therapies. This initiative aims to enhance the company’s clinical development efforts and expand its operations in oncology. Steven A. Shallcross, CEO, emphasized the significance of the board’s role in advancing their unique oncolytic adenovirus program to address critical cancers. The SAB includes notable members such as Ramon Alemany and Daniel DiMaio, renowned for their contributions to cancer treatment.
Synthetic Biologics, Inc. (NYSE American: SYN) announced an upcoming presentation on VCN-11, a next-generation oncolytic adenovirus, at the ASGCT Annual Meeting from May 16-19, 2022. The presentation, led by Dr. Ramon Alemany, will highlight preclinical data demonstrating VCN-11's potential to improve systemic delivery and effectively target tumors, even with high levels of neutralizing antibodies (NAbs). The company aims to advance its oncolytic adenovirus program through clinical development, building on its proof-of-mechanism data.
Synthetic Biologics (NYSE American: SYN) announced the publication of a Phase 1 study showing that the oncolytic adenovirus VCN-01 has an acceptable safety profile and promising clinical activity in patients with advanced solid tumors. The study, published in the Journal for ImmunoTherapy of Cancer, indicates that administration of VCN-01 is feasible, with viral exposure observed in both primary and metastatic tumors. The recommended Phase 2 dose (RP2D) was established at 1x1013 vp/patient. A Phase 2 trial in metastatic pancreatic adenocarcinoma is set to start in late 2022.
Synthetic Biologics has appointed Dr. Frank Tufaro as Chief Operating Officer, transitioning from his role at VCN Biosciences. He brings over 25 years of experience in biotech and oncolytic virus development. Dr. Manel Cascalló, also from VCN, is now General Director of the company's European subsidiary. This leadership change aims to leverage their expertise as Synthetic Biologics seeks to advance its clinical development strategy, particularly with the oncolytic adenovirus candidate, VCN-01. The new team aims to enhance shareholder value by achieving pivotal milestones in drug development.
Synthetic Biologics, Inc. (NYSE American: SYN) will provide a corporate update and participate in a panel discussion titled “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology” at the Maxim 2022 Virtual Growth Conference, scheduled for March 28-30, 2022. The discussion is set for March 28 at 12:00 p.m. ET. The company focuses on developing therapeutics for high unmet medical needs and recently acquired VCN Biosciences to enhance its oncolytic adenovirus platform. For further information, visit www.syntheticbiologics.com.
Synthetic Biologics (NYSE American: SYN) completed the acquisition of VCN Biosciences, enhancing its oncology pipeline. The FDA granted Orphan Drug Designation to VCN-01 for retinoblastoma. As of December 31, 2021, the company reported $67.3 million in cash, ensuring financial stability through 2023. With several milestones ahead, including multiple clinical trials for VCN-01 and SYN-004, the company looks forward to significant developments in 2022. However, the war in Ukraine may impact international trial costs.
Synthetic Biologics (NYSE American: SYN) has completed the acquisition of VCN Biosciences, enhancing its pipeline with oncolytic viruses aimed at cancer treatment. This acquisition includes VCN-01, an advanced clinical-stage drug for pancreatic ductal adenocarcinoma and retinoblastoma, both receiving Orphan Drug Designation. Total transaction value includes $4.7 million in cash and stock representing 19.99% of SYN's shares, plus milestone payments up to $66.5 million. Strong cash reserves support upcoming Phase 2 trials, showcasing SYN's commitment to advancing cancer therapies.
Synthetic Biologics (NYSE American: SYN) announced a conference call on March 16, 2022, to discuss its financial results for the year ending December 31, 2021, and provide a corporate update. The call will begin at 4:30 p.m. ET, with participants encouraged to dial in 15 minutes early. The company is focused on developing therapeutics for unmet medical needs and has recently entered an agreement to acquire VCN Biosciences, which is working on an oncolytic adenovirus platform for cancer treatment.
FAQ
What is the market cap of SYN (SYN)?
